Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	216 people Data from 1 RCT	Mean difference in average change in QTc LD (ms) from baseline (6 mg) with olanzapine (10 mg/day) with paliperidone (6 mg/day) Absolute results not reported	Mean difference 1.50 ms 95% CI 1.12 ms to 1.88 ms	Effect size not calculated	olanzapine
Systematic review	216 people Data from 1 RCT	Mean difference in average change in QTc LD (ms) from baseline (12 mg) with olanzapine (10 mg/day) with paliperidone (12 mg/day) Absolute results not reported	Mean difference –3.20 ms 95% CI –3.59 ms to –2.81 ms	Effect size not calculated	paliperidone
Systematic review	687 people 3 RCTs in this analysis	Mean difference in average change in cholesterol (mmol/L) with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	Mean difference –0.31 mmol/L 95% CI –0.44 mmol/L to –0.19 mmol/L	Effect size not calculated	paliperidone
Systematic review	687 people 3 RCTs in this analysis	Mean difference in average change in triglycerides (mmol/L) with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	Mean difference –0.32 mmol/L 95% CI –0.46 mmol/L to –0.17 mmol/L	Effect size not calculated	paliperidone
Systematic review	1317 people 3 RCTs in this analysis	Sleepiness with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 0.49 95% CI 0.37 to 0.65	Moderate effect size	paliperidone
Systematic review	433 people 3 RCTs in this analysis	Mean difference in average change in prolactin (ng/mL), men with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	Mean difference 26.81 ng/mL 95% CI 22.94 ng/mL to 30.68 ng/mL	Effect size not calculated	olanzapine
Systematic review	253 people 3 RCTs in this analysis	Mean difference in average change in prolactin (ng/mL), women with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	Mean difference 81.63 ng/mL 95% CI 68.31 ng/mL to 94.94 ng/mL	Effect size not calculated	olanzapine
Systematic review	660 people 3 RCTs in this analysis	Mean difference in average change in weight (kg) with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	Mean difference –0.88 kg 95% CI –1.38 kg to –0.37 kg	Effect size not calculated	paliperidone
Systematic review	1327 people 3 RCTs in this analysis	Extrapyramidal symptoms with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 2.99 95% CI 1.44 to 6.18	Moderate effect size	olanzapine
Systematic review	1327 people 3 RCTs in this analysis	Hyperkinesia with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 3.14 95% CI 1.53 to 6.42	Effect size not calculated	olanzapine
Systematic review	836 people 2 RCTs in this analysis	Hypertonia with olanzapine (10 mg/day) with paliperidone (6–12 mg/day) Absolute results not reported	RR 9.28 95% CI 1.26 to 68.51	Large effect size	olanzapine
Systematic review	502 people Data from 1 RCT	Akathisia: absent with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 0.90 95% CI 0.82 to 0.98	Small effect size	paliperidone
Systematic review	502 people Data from 1 RCT	Akathisia: questionable with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 1.19 95% CI 0.64 to 2.18		Not significant
Systematic review	502 people Data from 1 RCT	Akathisia: mild with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 1.02 95% CI 0.38 to 2.74		Not significant
Systematic review	502 people Data from 1 RCT	Akathisia: moderate with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 3.06 95% CI 0.17 to 56.52		Not significant
Systematic review	502 people Data from 1 RCT	Akathisia: marked with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 0.00 95% CI 0.00 to 0.00		Not significant
Systematic review	1327 people 3 RCTs in this analysis	Pain: headache with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 1.45 95% CI 1.03 to 2.04	Small effect size	olanzapine
Systematic review	1327 people 3 RCTs in this analysis	Suicide attempt with olanzapine (10 mg/day) with paliperidone (3–15 mg/day) Absolute results not reported	RR 0.69 95% CI 0.21 to 2.30		Not significant